You are here

home  ›  translational manufacturing at tri

 
 
Express Your Interest
Header Image

SCALE-UP BIOMEDICAL MANUFACTURING CAPABILITY
 

Due to open in 2026, TRI’s translational manufacturing facility will become Australia’s first scale-up multi-modal biomedical cGMP facility for maturing, high-potential, medtech and biotech startups. TM@TRI exists to enable exciting medical advances to reach maturity and keep manufacturing on Australian shores. It will attract a range of innovators, from those developing lifesaving medicines to new medical devices, capable of transforming health outcomes for patients.

Our unique biomedical cGMP model will provide expertise, specialist equipment, resourcing and support services normally out of reach for startups. This facility aims to significantly reduce the barrier to entry by becoming a trusted partner, able to support the journey through scale-up, technology transfer and execution. Start-up and non-commercial companies ready for at least Phase I clinical trial manufacturing will be able to manage their own manufacturing processes and product commercialisation pathway whilst maintaining their intellectual property and knowhow.

The outcome - delivery of new diagnostics, medical devices and therapies towards real-world impacts for patients.

 



 

At a glance
 

Icon 1

$100m

Proudly invested by the Queensland Government and TRI.

Icon 2

$37m

World class
state-of-the-art equipment.

Icon 3

500

Highly skilled science jobs.

Icon 4

Location

Situated on a tertiary teaching hospital campus within a thriving innovation precinct.


World-class facilities and support

TM@TRI will provide infrastructure, support and services at a greater scale to allow the start‐up companies born from local research discoveries to expand into scale‐up spaces.



 

Facilities

 
  • cGMP qualified facilities.
  • 5x commissioned, qualified and segregated cleanrooms.
  • Up-to ISO 7 (Grade B) capable cleanrooms.
  • Qualified utilities and 24/7 critical systems monitoring by BMS (Building Management System).
  • Continuous particle monitoring (fully qualified, 21CFR part 11 and PIC/S (Annex 11) compliant) Environmental Monitoring System (EMS).
  • PC2 certified laboratories.
  • Co-working desk spaces, including meeting rooms and pitch spaces.
  • Innovation space to support light engineering and chemistry (non GMP space).
  • Access to all TRI facilities, services and support including our dedicated clinical trial facilities.

     



Services
 

  • In-house Quality Assurance (QA) team with validated Quality Management System (QMS) framework.
  • Facilitation of Raw Material, Incoming Goods and Final Product disposition management.
  • Controlled Raw Material & Final Product storage (RT, 2-8°C, -70°C & cryo-storage).
  • cGMP consultancy and training.
  • Supply chain and logistical support.
  • Shared space facility cleaning, maintenance and environmental monitoring.
  • Core facility cGMP equipment maintenance and support (eg. autoclave).
  • Waste routing and management.
  • Tenant equipment implementation, commissioning, qualification, validation and calibration support.

     


Suitable Tenancies
 

TM@TRI’s infrastructure and facilities are not designed to operate as a CDMO. Tenants must meet New Process Introduction (NPI), Tech Transfer and Facility Fit criteria and as the product owner remain responsible for manufacturing activities, processes, regulatory licensing, and compliance.

TM@TRI will provide dedicated facility management, core cGMP systems, services and utilities, building maintenance, and support services for all shared spaces.

 

Suitable for:

Start-up and non-commercial companies at/or actively moving towards Phase I manufacturing (Australia).
 
Organisations with a specific requirement for cGMP cleanroom access.
 
Medical Technologies & Diagnostic companies with established Quality Compliance to support phase appropriate requirements.
 
Biologics/Therapeutic Sector - limited to Phase I (Australia).
 
Level 1 Innovation space (non-GMP area) suitable for chemistry and engineering groups.
 
Image 1

“We are well advanced on delivering a new chapter of biomedical manufacturing innovation for Australia with global significance. The addition of TM@TRI will transform TRI into the largest end-to-end translational research facility of its kind in Australia.”

David Crowley, General Manager - Translational Biomedical Manufacturing

 

 

 

 


Express your interest

Find out more about basing your business at Australia’s largest end-to-end translational research facility. Sign up to learn more.